Ketorolac

Ketorolac dosing must be carefully managed to minimize the risk of severe side effects. The standard approach involves starting with a parenteral (IV or IM) dose and then transitioning to oral therapy if necessary. The total duration of treatment across all routes must not exceed five days.

Parenteral (IV/IM) Dosing

• Patients < 65 years old: A single 60 mg IM dose or a 30 mg IV dose is common. For multiple-dose therapy, the recommended dose is 30 mg every 6 hours, not to exceed 120 mg per day.
• Patients ≥ 65 years, Renally Impaired, or < 50 kg (110 lbs): A single 30 mg IM dose or a 15 mg IV dose. For multiple-dose therapy, 15 mg every 6 hours, not to exceed 60 mg per day.

Oral Dosing (Continuation Therapy Only)

Oral ketorolac is only indicated as a follow-up to IV or IM ketorolac. It should never be used as the initial therapy.

• Patients < 65 years old: 20 mg as a first oral dose (after parenteral therapy), followed by 10 mg every 4 to 6 hours. The maximum daily oral dose is 40 mg.
• Patients ≥ 65 years, Renally Impaired, or < 50 kg: 10 mg every 4 to 6 hours. The maximum daily oral dose is 40 mg.

Ketorolac is not FDA-approved for use in pediatric patients under the age of 17 for oral or parenteral administration. However, it is occasionally used off-label in pediatric hospitals for short-term post-operative pain management under strict protocols. The ophthalmic solution is approved for children 2 years of age and older for allergic conjunctivitis and 3 years and older for post-cataract inflammation. Because of the high risk of renal toxicity and GI bleeding, pediatric use must be strictly supervised by a specialist.

Renal Impairment

Ketorolac is contraindicated in patients with advanced renal impairment and in patients at risk for renal failure due to volume depletion. For patients with moderately elevated serum creatinine, the dose should be reduced by half, and the total daily dose should not exceed 60 mg. Close monitoring of urine output and renal function tests is mandatory.

Hepatic Impairment

While ketorolac is primarily cleared renally, it is metabolized in the liver. Patients with impaired hepatic function should be monitored closely for signs of worsening liver enzymes. No specific dosage reduction is standardized for mild hepatic impairment, but the lowest effective dose should be used for the shortest possible time.

Elderly Patients

Patients over the age of 65 are at a significantly increased risk of gastrointestinal bleeding and acute kidney injury. Healthcare providers typically use the lower end of the dosing spectrum (15 mg IV/IM or 10 mg oral) and maintain strict adherence to the 5-day maximum duration.

• Oral Tablets: Should be swallowed whole with a full glass of water. Taking it with food or milk may help prevent stomach upset, though it may slightly delay the onset of pain relief. Do not crush or chew the tablets.
• Nasal Spray: If using the nasal spray, the bottle must be primed before the first use. One spray is typically administered in each nostril for a total dose of 31.5 mg, or one spray in a single nostril for a 15.75 mg dose, as directed by your doctor.
• Storage: Store all forms at room temperature (68°F to 77°F or 20°C to 25°C), away from moisture, heat, and direct light. Keep the nasal spray bottle in its child-resistant container when not in use.

Since ketorolac is usually given on a strict schedule in a hospital or for a very short duration at home, missing a dose should be addressed immediately. If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Never double the dose to catch up, as this significantly increases the risk of GI bleeding and kidney damage.

Signs of a ketorolac overdose may include severe abdominal pain, nausea, vomiting, gastrointestinal bleeding (manifesting as black/tarry stools or vomiting blood), lethargy, drowsiness, and rapid breathing. In severe cases, acute renal failure, hypertension, and coma can occur. If an overdose is suspected, contact a poison control center (1-800-222-1222) or seek emergency medical attention immediately. Treatment is primarily symptomatic and supportive; there is no specific antidote for ketorolac. Gastric lavage or activated charcoal may be used if the overdose is recent.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or extend the duration of treatment without medical guidance.

Ketorolac is a potent medication, and side effects are relatively common, particularly affecting the digestive system. Common side effects include:

• Gastrointestinal Upset: Nausea, dyspepsia (indigestion), and abdominal pain occur in up to 12-15% of patients. This is often described as a burning sensation in the upper stomach.
• Headache: Many patients report mild to moderate headaches shortly after administration.
• Drowsiness: Some patients feel tired or lethargic, though this is less common than with opioids.
• Dizziness: A feeling of lightheadedness or vertigo may occur, particularly when moving from a sitting to a standing position.

• Edema: Swelling of the hands, feet, or lower legs due to fluid retention.
• Hypertension: New-onset or worsening of high blood pressure.
• Tinnitus: Ringing in the ears.
• Pruritus: Itching of the skin or a mild rash.
• Constipation or Diarrhea: Changes in bowel habits are frequent during the short treatment window.
• Injection Site Pain: For those receiving IM or IV forms, localized pain or bruising at the site of injection is common.

• Aseptic Meningitis: Fever, neck stiffness, and confusion (rarely reported with NSAIDs).
• Liver Enzyme Elevation: Asymptomatic increases in ALT or AST levels.
• Visual Disturbances: Blurred vision or changes in color perception.
• Psychiatric Effects: Hallucinations, euphoria, or intense anxiety have been reported in rare instances.

> Warning: Stop taking Ketorolac and call your doctor immediately if you experience any of these.

• Gastrointestinal Bleeding: Symptoms include black, tarry, or bloody stools; coughing up blood; or vomit that looks like coffee grounds. This can occur without warning at any time during treatment.
• Anaphylaxis: Severe allergic reactions characterized by swelling of the face or throat, difficulty breathing, or hives. This is a medical emergency.
• Acute Kidney Injury: Signs include a sudden decrease in urine output, swelling in the ankles or feet, and shortness of breath.
• Cardiovascular Events: Chest pain, shortness of breath, sudden weakness on one side of the body, or slurred speech (signs of heart attack or stroke).
• Liver Toxicity: Yellowing of the skin or eyes (jaundice), dark urine, and severe right-sided abdominal pain.
• Severe Skin Reactions: Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN), which start as flu-like symptoms followed by a painful red or purplish rash that spreads and blisters.

Ketorolac is strictly contraindicated for long-term use. If used beyond 5 days, the risk of the following increases exponentially:

• Peptic Ulcer Disease: Development of deep sores in the stomach or duodenal lining.
• Chronic Kidney Disease: Permanent damage to the renal tubules and glomeruli.
• Increased Bleeding Risk: Prolonged inhibition of platelet aggregation can lead to easy bruising and difficulty stopping even minor bleeds.

The FDA has issued a comprehensive Black Box Warning for ketorolac, which is one of the most stringent in the NSAID class. The warning covers several critical areas:

1. 1Short-term Use Only: Ketorolac is indicated for the short-term (up to 5 days) management of moderately severe acute pain. It is NOT indicated for minor or chronic painful conditions.
2. 2Gastrointestinal Risk: Ketorolac can cause serious gastrointestinal adverse events including inflammation, bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk.
3. 3Cardiovascular Risk: NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction (heart attack), and stroke, which can be fatal. This risk may increase with duration of use.
4. 4Renal Risk: Ketorolac is contraindicated in patients with advanced renal impairment and in patients at risk for renal failure due to volume depletion.
5. 5Bleeding Risk: Ketorolac inhibits platelet function and is contraindicated in patients with suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, or incomplete hemostasis.
6. 6

Report any unusual symptoms to your healthcare provider immediately.

Ketorolac is a high-alert medication due to its potency and narrow therapeutic window. It must never be used for more than five days. Patients must be screened for history of ulcers, kidney disease, and bleeding disorders before the first dose is administered. It is essential to stay well-hydrated while taking ketorolac to protect the kidneys. If you are scheduled for surgery, inform your surgeon that you are taking or have recently taken ketorolac, as it can increase the risk of bleeding during and after the procedure.

The FDA-mandated Black Box Warning for Ketorolac Tromethamine is among the most extensive for any non-opioid medication. It emphasizes that ketorolac is for short-term use only (maximum 5 days) and carries severe risks of gastrointestinal bleeding, ulceration, and perforation. It also highlights the risk of cardiovascular thrombotic events, including fatal heart attack and stroke. Furthermore, it is contraindicated in patients with advanced renal impairment, those at risk of volume depletion, and those with a history of hypersensitivity to aspirin or other NSAIDs. The warning also explicitly forbids use as a prophylactic analgesic before major surgery or during labor and delivery.

• Allergic Reactions / Anaphylaxis Risk: Patients with the 'aspirin triad' (asthma, nasal polyps, and aspirin sensitivity) are at high risk for severe bronchospasm and anaphylaxis. If you have ever had a reaction to aspirin or ibuprofen, you must not take ketorolac.
• Hepatotoxicity: While rare, ketorolac can cause borderline elevations of liver tests. Severe hepatic reactions, including jaundice and fatal fulminant hepatitis, have been reported with NSAIDs. Monitoring for yellowing of the skin or eyes is necessary.
• Nephrotoxicity: Ketorolac can cause acute renal failure by reducing the production of renal prostaglandins, which are necessary to maintain blood flow to the kidneys. This is especially dangerous in patients who are dehydrated or taking diuretics.
• Hematologic Effects: Ketorolac inhibits platelet aggregation and may prolong bleeding time. Unlike aspirin, this effect is reversible within 24-48 hours after the drug is stopped, but it remains a significant risk for patients on anticoagulants.

For patients receiving ketorolac in a hospital setting, healthcare providers will typically monitor:

• Renal Function: Serum creatinine and Blood Urea Nitrogen (BUN) levels, especially in the elderly or those with pre-existing kidney issues.
• Liver Function: Periodic ALT/AST checks if treatment approaches the 5-day limit.
• Complete Blood Count (CBC): To check for signs of occult bleeding (low hemoglobin/hematocrit).
• Blood Pressure: Frequent monitoring as NSAIDs can cause sudden spikes in blood pressure.
• Fluid Balance: Monitoring for edema and weight gain.

Ketorolac may cause dizziness, drowsiness, or visual disturbances in some patients. You should not drive, operate heavy machinery, or engage in hazardous activities until you know how the medication affects you. If you feel lightheaded or sleepy, avoid these tasks and consult your doctor.

Alcohol consumption should be strictly avoided while taking ketorolac. Alcohol significantly increases the risk of gastrointestinal irritation and bleeding. Combining the two can lead to rapid development of stomach ulcers or severe gastritis.

Because ketorolac is only used for 5 days or less, there is no risk of a 'withdrawal syndrome' like that seen with opioids. However, the drug should be stopped immediately if any signs of an allergic reaction, GI bleed, or kidney dysfunction occur. There is no need for tapering when used for the indicated short duration.

> Important: Discuss all your medical conditions with your healthcare provider before starting Ketorolac.

Certain medications must NEVER be used in combination with ketorolac due to the risk of life-threatening complications:

• Other NSAIDs (e.g., Ibuprofen, Naproxen, Celecoxib): Using multiple NSAIDs simultaneously exponentially increases the risk of gastrointestinal perforation and renal failure.
• Probenecid: This gout medication significantly decreases the clearance of ketorolac, leading to dangerously high plasma levels and increased toxicity.
• Pentoxifylline: Combining these drugs increases the risk of systemic bleeding.
• Aspirin: Even low-dose aspirin for heart health should be avoided unless specifically directed by a doctor, as it increases the risk of major GI bleeds.

• Anticoagulants (e.g., Warfarin, Heparin, Apixaban): Ketorolac inhibits platelet function and can irritate the stomach lining, making a catastrophic bleed much more likely when combined with blood thinners.
• Lithium: Ketorolac reduces the renal clearance of lithium, which can lead to lithium toxicity (tremors, confusion, seizures).
• Methotrexate: NSAIDs can reduce the excretion of methotrexate, leading to bone marrow suppression and GI toxicity.
• ACE Inhibitors and ARBs (e.g., Lisinopril, Losartan): Ketorolac can reduce the blood-pressure-lowering effects of these drugs and significantly increase the risk of acute kidney failure (the 'triple whammy' when combined with diuretics).

• Diuretics (e.g., Furosemide, Hydrochlorothiazide): Ketorolac can reduce the natriuretic (salt-clearing) effect of diuretics and increase the risk of nephrotoxicity.
• SSRIs (e.g., Fluoxetine, Sertraline): These antidepressants also affect platelet function; combining them with ketorolac increases the risk of upper gastrointestinal bleeding.
• Corticosteroids (e.g., Prednisone): Increased risk of gastrointestinal ulceration.
• Digoxin: Ketorolac may increase serum digoxin levels in some patients.

• High-Fat Meals: As noted in the pharmacokinetics section, high-fat food can delay the absorption of oral ketorolac by up to an hour. For acute pain, it is best taken on an empty stomach, though food may be used if stomach upset occurs.
• Alcohol: Increases the risk of GI bleeding and should be avoided entirely.
• Caffeine: While not a direct contraindication, excessive caffeine can worsen the stomach irritation caused by NSAIDs.

• Ginkgo Biloba, Garlic, Ginger, and Ginseng: These supplements have mild anti-platelet effects and may increase the risk of bleeding when taken with ketorolac.
• St. John's Wort: May theoretically affect the metabolism of many drugs, though the clinical significance with ketorolac is low.
• Omega-3 Fatty Acids (Fish Oil): High doses can have blood-thinning effects and should be used cautiously.

• Liver Function Tests: May show false elevations in transaminases.
• Bleeding Time: Will be prolonged for 24-48 hours after the last dose.
• Urine Tests: Ketorolac may cause a false-positive result for certain urine protein tests depending on the methodology used.

For each major interaction, the mechanism typically involves either the competitive inhibition of renal transporters (like with Lithium or Methotrexate) or the synergistic inhibition of physiological pathways (like the dual inhibition of platelets with anticoagulants). The management strategy usually involves avoiding the combination or performing frequent laboratory monitoring of renal function and drug levels.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Ketorolac must NEVER be used in patients with the following conditions:

• Active Peptic Ulcer Disease: Or a history of recent GI bleeding or perforation. The drug's potent inhibition of protective prostaglandins will worsen these conditions and may cause fatal hemorrhage.
• Advanced Renal Impairment: Patients with a creatinine clearance < 30 mL/min or those at risk for renal failure due to volume depletion (dehydration). Ketorolac can trigger immediate, acute renal shut-down.
• Labor and Delivery: It can cross the placenta and cause premature closure of the ductus arteriosus in the fetus and inhibit uterine contractions in the mother.
• Hypersensitivity: Any previous allergic reaction to ketorolac, aspirin, or other NSAIDs (e.g., Ibuprofen-induced asthma).
• Suspected Cerebrovascular Bleeding: Due to its effect on platelet aggregation, it can worsen internal bleeding in the brain.
• Peri-operative Use: Specifically in the setting of Coronary Artery Bypass Graft (CABG) surgery.

These conditions require a careful risk-benefit analysis by a physician:

• Mild to Moderate Renal Impairment: Requires significant dose reduction and monitoring.
• Congestive Heart Failure: The fluid retention caused by ketorolac can exacerbate heart failure symptoms.
• Asthma: Especially if the patient has a history of aspirin-sensitive asthma.
• Coagulation Disorders: Patients with hemophilia or other bleeding tendencies.
• Hepatic Cirrhosis: Increased risk of renal failure and bleeding.

There is a high rate of cross-sensitivity between ketorolac and other NSAIDs. If a patient has experienced hives, swelling, or bronchospasm after taking aspirin, naproxen, or ibuprofen, they are highly likely to have a similar or more severe reaction to ketorolac. This is known as 'NSAID-exacerbated respiratory disease' (NERD).

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Ketorolac.

Ketorolac is generally avoided during pregnancy. According to FDA guidelines, use of NSAIDs like ketorolac at about 20 weeks gestation or later may cause fetal renal dysfunction leading to oligohydramnios (low amniotic fluid) and, in some cases, neonatal renal impairment. In the third trimester (starting at 30 weeks), ketorolac is strictly contraindicated because it may cause premature closure of the fetal ductus arteriosus (a vital heart vessel in the fetus) and lead to pulmonary hypertension in the newborn. It may also delay labor by inhibiting uterine contractions.

Ketorolac is excreted in human milk in small concentrations. While the amount transferred to the infant is generally considered low, the potential for serious adverse effects (such as GI bleeding or renal issues) in the nursing infant must be considered. Most clinicians advise caution, and some recommend avoiding breastfeeding during the 5-day course of treatment or using an alternative analgesic like acetaminophen.

Safety and effectiveness in pediatric patients under 17 years of age have not been established for systemic ketorolac. While it is used off-label in pediatric surgical centers, the risk of acute kidney injury is higher in children, especially those who are not well-hydrated. The ophthalmic form is approved for children 2 years and older.

Patients over age 65 are at the highest risk for severe complications from ketorolac. Age-related declines in renal function mean that the drug stays in the body longer, increasing the risk of toxicity. The FDA recommends using the lowest possible dose (15 mg IV/IM or 10 mg oral) and monitoring these patients very closely for signs of GI bleeding or kidney failure. Geriatric patients are also more susceptible to the cardiovascular risks of NSAIDs.

Ketorolac is cleared almost entirely by the kidneys. In patients with serum creatinine levels indicating mild to moderate impairment, the dose must be reduced by 50%, and the daily maximum should not exceed 60 mg. In patients with advanced renal disease (Scr > 3.0 mg/dL), the drug is absolutely contraindicated. It is not significantly removed by hemodialysis.

Patients with impaired hepatic function (e.g., Child-Pugh Class A or B) do not typically require a dose adjustment, but they should be monitored for signs of worsening liver function. In patients with severe cirrhosis, the risk of developing 'hepatorenal syndrome' is increased when using potent NSAIDs like ketorolac.

> Important: Special populations require individualized medical assessment.

Ketorolac is a potent inhibitor of the cyclooxygenase (COX) enzyme system. Specifically, it acts as a competitive antagonist for the active site of both COX-1 and COX-2 enzymes. By binding to these enzymes, it prevents the oxygenation of arachidonic acid into cyclic endoperoxides, which are the precursors to prostaglandins, thromboxanes, and prostacyclin. Ketorolac is considered one of the most potent COX-1 inhibitors available, which contributes to its high analgesic efficacy but also its significant gastrointestinal toxicity. The S-enantiomer is responsible for almost all the COX-inhibitory activity. Its EPC classification as an alpha-1 adrenergic agonist suggests potential minor interactions with vascular receptors, though this is not its primary clinical mechanism.

The primary pharmacodynamic effect of ketorolac is analgesia. It does not have significant sedative or anxiolytic properties. The onset of analgesic action following IM administration is approximately 30 minutes, with a peak effect occurring at 1 to 2 hours. The duration of analgesia is typically 4 to 6 hours. Unlike opioids, ketorolac does not cause miosis (pupil constriction) or significant respiratory depression. It does, however, cause a dose-related inhibition of platelet aggregation that lasts for 24 to 48 hours after discontinuation.

| Parameter | Value |

|---|---|

| Bioavailability | 80% - 100% |

| Protein Binding | >99% |

| Half-life | 5 - 6 hours (up to 12h in elderly) |

| Tmax | 0.5 - 1.0 hours (oral) |

| Metabolism | Hepatic (Glucuronidation/Hydroxylation) |

| Excretion | Renal 91%, Fecal 6% |

Ketorolac tromethamine is a member of the pyrrolo-pyrrole group of nonsteroidal anti-inflammatory drugs. Its chemical name is (±)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, compounded with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1). The molecular formula is C15H13NO3 · C4H11NO3, and its molecular weight is 376.41 g/mol. It is a white to off-white crystalline powder that is highly soluble in water and methanol.

Ketorolac is classified as a non-selective NSAID. Within the NSAID category, it is further grouped into the heteroaryl acetic acid derivatives, alongside drugs like indomethacin and diclofenac. It is distinct from the propionic acid derivatives (like ibuprofen) and the oxicams (like piroxicam) due to its unique pyrrolo-pyrrole structure and its exceptional potency as an analgesic.